Analyst Ratings for [VRTX] Vertex Pharmaceuticals Incorporated

2/12/25	Upgrades	Sell Hold	X
VRTX Vertex Pharma Canaccord Genuity
$408 $424
2/11/25	Upgrades	Sell Hold	X
VRTX Vertex Pharma Canaccord Genuity
1/30/25	Downgrades	Overweight Eq Weight	X
VRTX Vertex Pharma Wells Fargo
$460
12/20/24	Reiterated	Buy	X
VRTX Vertex Pharma H.C. Wainwright
$600 $535
12/19/24	Downgrades	Outperform Perform	X
VRTX Vertex Pharma Oppenheimer
12/9/24	Upgrades	Hold Buy	X
VRTX Vertex Pharma Jefferies
$500 $550
11/14/24	Initiated	Buy	X
VRTX Vertex Pharma Citigroup
$575
10/16/24	Initiated	Sector Perform	X
VRTX Vertex Pharma Scotiabank
10/10/24	Resumed	Mkt Perform	X
VRTX Vertex Pharma Raymond James
8/5/24	Downgrades	Overweight Eq Weight	X
VRTX Vertex Pharma Barclays
$472 $509
6/27/24	Initiated	Buy	X
VRTX Vertex Pharma Redburn Atlantic
$545
4/11/24	Upgrades	In-line Outperform	X
VRTX Vertex Pharma Evercore ISI
$438
2/15/24	Initiated	Outperform	X
VRTX Vertex Pharma Wolfe Research
$515
2/6/24	Downgrades	Outperform In-line	X
VRTX Vertex Pharma Evercore ISI
$436 $438
2/2/24	Downgrades	Outperform Mkt Perform	X
VRTX Vertex Pharma Bernstein
1/31/24	Downgrades	Buy Hold	X
VRTX Vertex Pharma Maxim Group
1/31/24	Downgrades	Neutral Underperform	X
VRTX Vertex Pharma Robert W. Baird
$325
1/24/24	Downgrades	Hold Sell	X
VRTX Vertex Pharma Canaccord Genuity
$332 $379
12/14/23	Reiterated	Sector Perform	X
VRTX Vertex Pharma RBC Capital Mkts
$347 $379
5/30/23	Initiated	Outperform	X
VRTX Vertex Pharma William Blair
$382
5/4/23	Resumed	Overweight	X
VRTX Vertex Pharma Piper Sandler
$385
3/21/23	Initiated	Outperform	X
VRTX Vertex Pharma Bernstein
$344
1/18/23	Initiated	Hold	X
VRTX Vertex Pharma Canaccord Genuity
$311
1/17/23	Upgrades	Mkt Perform Outperform	X
VRTX Vertex Pharma SVB Leerink
$374
12/19/22	Downgrades	Buy Hold	X
VRTX Vertex Pharma Jefferies
$340
7/13/22	Initiated	Overweight	X
VRTX Vertex Pharma Cantor Fitzgerald
$365
6/1/22	Upgrades	Hold Buy	X
VRTX Vertex Pharma Maxim Group
$325
5/23/22	Initiated	Mkt Perform	X
VRTX Vertex Pharma SVB Leerink
$265
5/6/22	Downgrades	Outperform Neutral	X
VRTX Vertex Pharma Robert W. Baird
$250
5/3/22	Upgrades	Underweight Eq-Weight	X
VRTX Vertex Pharma Morgan Stanley
$250
2/3/22	Downgrades	Outperform Sec Perform	X
VRTX Vertex Pharma RBC Capital Mkts
$269
1/27/22	Reiterated	Overweight	X
VRTX Vertex Pharma JP Morgan
$260 $288
1/27/22	Reiterated	Underweight	X
VRTX Vertex Pharma Morgan Stanley
$203 $208
1/27/22	Reiterated	Outperform	X
VRTX Vertex Pharma RBC Capital Mkts
$268 $269
1/27/22	Reiterated	Hold	X
VRTX Vertex Pharma Stifel
$213 $222
1/27/22	Reiterated	Outperform	X
VRTX Vertex Pharma Wolfe Research
$271 $282
1/20/22	Upgrades	Mkt Perform Outperform	X
VRTX Vertex Pharma BMO Capital Markets
$202 $274
12/9/21	Initiated	Overweight	X
VRTX Vertex Pharma Wells Fargo
$270
11/19/21	Initiated	Market Perform	X
VRTX Vertex Pharma BMO Capital Markets
$202
11/19/21	Downgrades	Overweight Neutral	X
VRTX Vertex Pharma Piper Sandler
$323 $218
7/20/21	Downgrades	Mkt Perform Underperform	X
VRTX Vertex Pharma SVB Leerink
$170
7/19/21	Resumed	Outperform	X
VRTX Vertex Pharma Wolfe Research
$252
7/1/21	Initiated	Mkt Perform	X
VRTX Vertex Pharma Raymond James
6/11/21	Downgrades	Outperform Neutral	X
VRTX Vertex Pharma Daiwa Securities
$210
2/23/21	Upgrades	Neutral Outperform	X
VRTX Vertex Pharma Robert W. Baird
$220 $252
2/2/21	Reiterated	Buy	X
VRTX Vertex Pharma H.C. Wainwright
$315 $275
12/30/20	Initiated	Outperform	X
VRTX Vertex Pharma Daiwa Securities
$250
8/1/19	Downgrades	Buy Hold	X
VRTX Vertex Pharma Needham
5/23/19	Resumed	Buy	X
VRTX Vertex Pharma Citigroup
$205
5/21/19	Initiated	Outperform	X
VRTX Vertex Pharma Credit Suisse
$209
4/12/19	Initiated	In-line	X
VRTX Vertex Pharma Evercore ISI
3/26/19	Upgrades	Mkt Perform Outperform	X
VRTX Vertex Pharma William Blair
3/19/19	Downgrades	Outperform Mkt Perform	X
VRTX Vertex Pharma SVB Leerink
2/6/19	Downgrades	Buy Hold	X
VRTX Vertex Pharma Maxim Group
1/2/19	Downgrades	Outperform Mkt Perform	X
VRTX Vertex Pharma Raymond James
10/26/18	Upgrades	Neutral Buy	X
VRTX Vertex Pharma H.C. Wainwright
$220
10/1/18	Initiated	Overweight	X
VRTX Vertex Pharma Cantor Fitzgerald
$217
8/7/18	Reiterated	Buy	X
VRTX Vertex Pharma Stifel
$182 $200
3/5/18	Reiterated	Buy	X
VRTX Vertex Pharma Maxim Group
$195 $200
2/13/18	Reiterated	Mkt Outperform	X
VRTX Vertex Pharma JMP Securities
$200 $211
2/1/18	Reiterated	Overweight	X
VRTX Vertex Pharma Barclays
$180 $200

VRTX Vertex Pharmaceuticals Incorporated

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.